Abstract: Particles with a spatial and/or temporal release profile for delivery of different agents at different times to the same cells of a subject have been developed. The particles include a core polymeric particle containing a polymer and a first agent, a tethering moiety, covalent linker or covalent linkage attached to the core particle, and a tethered particle attached to the particle via the tethering moiety, covalent linker or covalent linkage and containing a second agent, where the agents are released at different times within or to the same cells. The first and second agents may be a therapeutic or prophylactic agent, such as an antigen, an immunomodulator, an anti-neoplastic agent, a hormone, an inhibitor, etc. The particles may form compositions for treating diseases with a spatial and/or temporal treatment regimen.

Abstract: The invention relates to compositions and methods for adjusting digestive or absorptive rates and ratio of foods or drinks or reducing a digestive solution. Particularly, the invention provides a composition comprising an insoluble dietary fiber and a prebiotic gel and its application in reducing digestive or absorptive rates and ratio of foods or drinks.

Abstract: Disclosed herein is a method for treating an inflammatory disease in a subject, including administering to the subject a therapeutically effective amount of a dihydrolipoic acid (DHLA) coated gold nanocluster about 0.1 to 20 nm in diameter. Also disclosed is a method for reducing the expression of a pro-inflammatory molecule in a cultured cell, including contacting the cultured cell with the said DHLA coated gold nanocluster. Still disclosed is a pharmaceutical composition that includes the present DHLA coated gold nanocluster. The pharmaceutical composition is useful for treating the inflammatory disease in the subject.

Abstract: Currently, the present invention provides a pH-sensitive lipid nanoparticle, comprising: a nanoparticle core composed of a mixture of lipid and/or surfactant, and the surface of the nanoparticle core comprising: a imine-omPEG, the imine is a pH-sensitive linker; and a PEG-peptide, wherein the peptide is selected from the group consisting of a RF peptide, a K peptide, and a H peptide; wherein the RF peptide is a potent CPP, the K peptide is a mitochondria-targeting peptide and the H peptide is a cancer specific binding peptide; a lipid, inside the nanoparticle core; wherein the lipid nanoparticle encapsulating a targeting agent.

Abstract: Disclosed are targeted lipid based particles for delivery of nucleic acid molecules (such as siRNA) to leukocytes (such as T-Cells and B-cells). Further disclosed are uses of the targeted lipid based particles for treating Leukocytes-associated diseases, such as, cancer.

Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting DNM2 expression, which may be useful for treating, preventing, or ameliorating a disease associated with DNM2.

Abstract: The present application provides an oral care composition comprising: a) one or more omega fatty acids; and one or more of the following: b) one or more emulsifying agents; c) one or more protease enzymes; d) one or more soluble calcium phosphate remineralizing agents; e) one or more amino acids.

Abstract: Disclosed herein are novel compounds, pharmaceutical compositions comprising such compounds and related methods of their use. The compounds described herein are useful, e.g., as liposomal delivery vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and subsequent transfection of said target cells, and in certain embodiments are characterized as having one or more properties that afford such compounds advantages relative to other similarly classified lipids.

Abstract: Composition and method for treatment of Alzheimer's disease that includes ANAVEX2-73. Method of treatment of Alzheimer's disease using pharmaceutical compositions comprising ANAVEX2-73 according to an intermittent dosage regimen.

Abstract: The present disclosure relates to the synergistic liposomal formulation comprising, phophatidylcholine, stearylamine and anticancer drugs for the treatment of cancer. The PC:SA cationic liposome encapsulated camptothecin (CPT) and doxorubicin (DOX) formulations show enhanced synergistic anti-cancer effect and provide improved therapeutic index as compared to either the liposome or drug alone. The present disclosure also relates to the use of Cationic liposomal preparation of phosphatidylcholine:stearylamine (PC:SA) showing anticancer effect. The SA-bearing liposome and drug entrapped in the liposome are effective against cancer both in vitro and in vivo, without causing any adverse effect on host.

Abstract: There is provided a powder composition comprising a collection of particles (I) having median particle diameter of 10 micrometers to 200 micrometers, wherein each of said particles (I) comprises (a) a covering of a fatty compound having melting point of 50° C. to 110° C. and (b) one or more inner particles (II) comprising one or more complex that contains a cyclopropene compound molecule or a portion of a cyclopropene compound molecule encapsulated in a molecule of a molecular encapsulating agent. Also provided is a slurry comprising water and such a powder. Also provided is a method of contacting plants or plant parts with such a slurry.

Abstract: The invention is directed towards methods and compositions for preventing dusting problems in mineral supplement. The method involves treating the mineral supplement or a dust releasing material with a composition comprising polymerized organic acid.

Abstract: There is provided a powder composition comprising a collection of particles (I) having median particle diameter of 10 micrometers to 200 micrometers, wherein each of said particles (I) comprises (a) a covering of a fatty compound having melting point of 50° C. to 110° C. and (b) one or more inner particles (II) comprising one or more complex that contains a cyclopropene compound molecule or a portion of a cyclopropene compound molecule encapsulated in a molecule of a molecular encapsulating agent. Also provided is a slurry comprising water and such a powder. Also provided is a method of contacting plants or plant parts with such a slurry.

Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to prevent obesity and/or improve body composition later in life.

Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a lipid globules coated with polar lipids. The composition can be used to prevent obesity and/or improve body composition later in life.

Abstract: The present invention relates to coated extended release pharmaceutical formulations of valsartan comprising a core comprising valsartan and at least one coating layer over the core. The present invention further relates to extended release pharmaceutical formulations comprising (a) a core comprising valsartan and at least one hydrophilic swelling polymer and (b) at least one coating layer over the core wherein the coating layer in contact with the core is applied from an organic solvent based system.

Abstract: The present invention generally relates to yeast cell wall microparticles loaded with nanoparticles for receptor-targeted nanoparticle delivery. In particular, the present invention relates to trapping nanoparticles either on the surface or inside a yeast glucan particles, for example, yeast glucal particles. The present invention further relates to methods of making the yeast cell wall particles loaded with nanoparticles. The present invention also relates to methods of using the yeast cell wall particles loaded with nanoparticles for receptor-targeted delivery of the nanoparticles, e.g., drug containing nanoparticles.

Abstract: This disclosure relates to methods of treating anal gland disease in subjects. In particular, the disclosure provides supplement compositions useful for treatment of anal gland disease. Such compositions comprise a probiotic, a fiber source, and an anti-inflammatory agent.

Abstract: The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, to a subject having one or more symptoms of hormonal variations.

Abstract: Methods and compositions are provided for generating and applying long-lasting therapeutic nitric oxide (NO) gas from the reaction of a least one microencapsulated nitrite salt and an activating volume of an aqueous acidified gel that has sufficient acidity to convert the nitrite salt to a nitric oxide (NO) and further provides a reducing property that retains the NO in bioactive form.

Abstract: The invention is directed towards methods and compositions for preventing dusting problems in mineral supplement. The method involves treating the mineral supplement or a dust releasing material with a composition comprising polymerized organic acid.

Abstract: The invention relates to an enteric-coated capsule containing cationic nanoparticles for oral insulin delivery, in particular to a type of cationic nanoparticle including a polycationic and mucoadhesive polymer and a biodegradable polymer, wherein each of the nanoparticles has positive surface charge and enhanced permeability for paracellular insulin delivery; the enteric-coated capsule further includes a pH-sensitive polymer as the coating. The enteric-coated capsule containing cationic nanoparticles, when being orally administered to a subject, are configured to prevent the acidic degradation of the active substance such as insulin before being released from said cationic nanoparticles to a specific absorption site along the gastrointestinal tract.

Abstract: Compositions including at least 3?-tert-butyl-4?-(2-hydroxy-ethoxy)-4?-pyrrolidin-1-yl-[1,1?;3,1?]-terphenyl-4-carboxylic acid are described. The compositions can be oil-in-water emulsions made up of oily liquid globules each provided with a lamellar liquid crystal coating dispersed in an aqueous phase; a retinoid is either in the oily liquid globules or in the aqueous phase; each oily liquid globule is individually coated with a unilamellar or oligolamellar layer, obtained from at least one lipophilic surfactant, at least one hydrophilic surfactant and at least one separate anionic surfactant, and the coated oily liquid globules have a mean diameter lower than 800 nm.

Abstract: The present invention discloses a heat therapy kit for malignant tumor treatment that comprises a pharmaceutical agent containing anti-regulatory T cell antibody and a pharmaceutical agent containing magnetic fine particles, and a heat therapy method that uses that kit.

Abstract: Compositions and methods for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder are described herein. The compositions contain a nanolipogel for sustained delivery of an effective amount of one or more active agents of choice, preferably a drug for treating or ameliorating the symptoms of inflammatory or autoimmune disease or disorder. The nanolipogel includes a lipid bilayer surrounding a hydrogel core, which may optionally include a host molecule, for example, an absorbent such as a cyclodextrin or ion-exchange resin. In preferred embodiments at least one of active agents is an immunosuppressant.

Abstract: A process for preparing nanocapsules with a liquid lipid core and a solid lipid shell, charged with at least one active agent. The process contains at least the steps of formulating a microemulsion by phase inversion of an emulsion, totally or partially forming from at least one active agent a second composition different than the microemulsion, placing the microemulsion in contact with the second composition under conditions suitable for interaction of the active agent with the microemulsion, and chill-hardening the microemulsion that has interacted with the active agent, to obtain the nanocapsules.

Abstract: Methods and compositions, including nucleotide sequences, amino acid sequences, and host cells, for producing fatty alcohols are described.

Abstract: Disclosed is a topical skin care composition and corresponding methods for its use comprising water, a cationic surfactant, an occlusive skin conditioning agent, a humectant skin conditioning agent, and a silicone containing compound. The composition is dermatologically acceptable and is capable of moisturizing skin for at least twelve hours after topical application to skin even after multiple washings of the skin.

Abstract: Provided are compositions containing melatonin and zinc. Additionally provided are dosage forms containing the compositions, and methods of making the compositions and dosage forms. Methods of removing mercury from the body of subject are provided, as are methods of treating and/or preventing certain conditions associated with mercury toxicity.

Abstract: A “nanolipogel” is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.

Abstract: A pharmaceutical composition comprising an amphiphilic emulsifier, a polar liquid carrier and, optionally, a lipid component. The amphiphilic emulsifier form free-moving, optionally lipid-carrying, micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure and correct hypovolemia.

Abstract: The invention provides nanoparticles containing a nucleic acid nanostructure, of defined shape and size, linked to a hydrophobic moiety and coated by lipids, compositions comprising the nanoparticles, and methods of producing and methods of using the nanoparticles.

Abstract: The present invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides in the treatment, prevention and/or amelioration of otic diseases or conditions.

Abstract: The present invention relates to pharmaceutical powders for inhalation produced by a method consisting of a first step of mixing particles of a force-controlling agent selected from a salt of a fatty acid with particles of one or more pharmacologically active materials and a second step of sieving or blending the powder with a carrier material.

Abstract: The present disclosure describes economical processes to improve the bioavailability of nutraceuticals by formulations that induce micronization and sustained release. The inventive process can be used to increase the solubility and bioavailability of lipophilic and moderately water-soluble nutraceuticals by combining excipients that increase the solubility and induce sustained release of the active compounds. The inventive process also can be used to increase the residence time of highly water-soluble nutraceuticals that are metabolized and eliminated quickly from the body, consequently increasing the therapeutic potential. The disclosed formulations advantageously are freely flowing powders that can be used to formulate with other ingredients into tablets, capsules, or the like; or used as bulk powders.

Abstract: The present disclosure refers to strains of lactic bacteria and/or bifidobacteria having activity of inhibiting/reducing the growth of different biotypes of E. coli, including E. coli 0157:7 and different biotypes of clostridia, including Clostridium difficile, Listeria monocytogenes, Enterococcus sp. and Klebsiella sp. Furthermore, the present invention refers to a pharmaceutical or dietary composition or a supplement or a medical device with at least one of the said strains of bacteria, optionally in combination with acetylcysteine and/or microencapsulated gastroprotected lysozyme and/or acetylcysteine with microencapsulated gastro-protected lysozyme.

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.

Abstract: Provided herein are methods and compositions for producing formulations systemic delivery of dopamine agonists via the oral inhalation route. Specifically, provided herein are methods and compositions for a formulation of rotigotine that is suitable for administration via oral inhalation. Such methods and compositions are useful in the treatment or amelioration of one or more Parkinson's disease symptom(s).

Abstract: Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate.

Abstract: A process is described for obtaining free flowable, carrier free powders from aqueous solutions of deliquescent quaternary ammonium compounds in a two step process, comprising a drying and a powder mixing step. The excellent free-flowing and stability characteristics of the final product could only be obtained when among possible other additives at least one univalent metal fatty acid salt is added to the liquid phase in the drying step and at least one multivalent metal fatty acid salt in the powder mixing step. A surprising synergy was observed between these additives when applied as described in the present invention.

Abstract: A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excipient(s).

Abstract: A stable taste masked, pharmaceutical composition comprising a plurality of coated, non-disintegrating discrete dosage units, said units comprising of a core comprising one or more cephalosporins such as cefuroxime axetil and cefpodoxime proxetil and one or more coating layers. Cefuroxime axetil is in ?-crystalline and amorphous forms, where at least 30% of the Cefuroxime axetil is in the ?-crystalline form, wherein the particle size distribution of the ?-crystalline form being such that 100% of the particles have a particle size below 250?. The ratio of the crystalline fraction to the amorphous fraction ranges from 0.3:0.7 to 0.99:0.01. The particle size of cefpodoxime proxetil is such that 90% of the particles are below 15?.

Abstract: Implantable biomaterials, particularly hydrogel substrates with porous surfaces, and methods for enhancing the compatibility of biomaterials with living tissue, and for causing physical attachment between biomaterials and living tissues are provided. Also provided are implants suitable for load-bearing surfaces in hard tissue repair, replacement, or augmentation, and to methods of their use. One embodiment of the invention relates to an implantable spinal disc prosthesis.

Abstract: A composition comprising at least one substance coated with an agent wherein the agent forms a liquid impermeable but gas permeable layer surrounding the said substance and preventing the passage of the said substance through said coating, wherein in-use the said substance is not released into solution in the body, and wherein said substance is selected from one or more of the group consisting of calcium phosphate, sodium chloride, potassium chloride, magnesium chloride, calcium carbonate, and sodium bicarbonate for use in the treatment of osteoporosis and other bone conditions.

Abstract: A modified release composition comprising tacrolimus which is useful for the treatment or prevention of rejection reactions by transplantation of organs or tissues.

Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a lipid globules coated with phospholipids. The composition is used for increasing bone mineral content, bone mineral density, preventing osteoporosis, and/or preventing ostopenia.

Abstract: The present invention relates to methods of making a powder for inhalation comprising a first step of mixing particles of a force-controlling agent selected from the group consisting of phospholipids, titanium dioxide, aluminum dioxide, silicon dioxide, starch, and salts of fatty acids, with particles of one or more pharmacologically active materials, wherein the mixing is achieved by one or more of the processes of sieving, mixing or blending, and wherein the mixing results in the particles of the force-controlling agent being disposed on the surface of the particles of the one or more pharmacologically active materials as either a particulate coating or as a continuous or discontinuous film.

Abstract: The invention provides multivalent surface-crosslinked micelle (SCM) particles, crosslinked reverse micelle (CRM) particles, and methods of making and using them. The SCM particles can be used, for example, to inhibit a virus or bacteria from binding to a host cell. The inhibition can be used in therapy for the flu, cancer, or AIDS. The CRM particles can be used, for example, to prepare metal nanoparticles or metal alloy nanoparticles, or they can be used in catalytic reactions.

Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.

Abstract: The invention concerns a rigid shaped article essentially consisting of a plurality of mutually adhering grains of sand provided with a coating consisting of wax, for the elimination or relief of itching. In a particular embodiment of the invention, the wax essentially consists of beeswax.